\"We are excited to establish this long term relationship with AstraZeneca who are now establishing themselves as a leader in genomic-focused research,\" said J. Craig Venter, Ph.D., Co-founder and CEO, HLI. \"We look forward to working together to use HLI's proprietary computational methods and genomic data insights to better inform clinical trials and drug development.\" <\/p>\n
The HLI Knowledgebase, which was recently awarded a 2016 Bio-IT World Best Practice Award, is a key tool in the company's portfolio to transform how medicine is practiced. The Knowledgebase contains tens of thousands of high-quality samples with genomic and phenotypic data and can be used to help customers streamline drug development, aid in discovery of biomarker and companion diagnostics, and rescue and repurpose drugs from failed clinical trials. <\/p>\n
About Human Longevity, Inc.Human Longevity, Inc. (HLI) is the genomics-based, technology-driven company creating the world's largest and most comprehensive database of whole genome, phenotype and clinical data. HLI is developing and applying large scale computing and machine learning to make novel discoveries to revolutionize the practice of medicine. HLI's business also includes the HLI Health Nucleus, a genomic powered clinical research center which uses whole genome sequence analysis, advanced clinical imaging and innovative machine learning, along with curated personal health information, to deliver the most complete picture of individual health. For more information, please visit http:\/\/www.humanlongevity.com<\/a> or http:\/\/www.healthnucleus.com<\/a>. <\/p>\n Logo - http:\/\/photos.prnewswire.com\/prnh\/20140304\/LA76169LOGO<\/a> <\/p>\n<\/p>\n To view the original version on PR Newswire, visit:http:\/\/www.prnewswire.com\/news-releases\/human-longevity-inc-announces-10-year-deal-with-astrazeneca-to-sequence-and-analyze-patient-samples-from-astrazeneca-clinical-trials-300255548.html<\/a> <\/p>\n SOURCE Human Longevity, Inc. <\/p>\n